Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Trypanosoma cruzi calreticulin inhibits the complement lectin pathway activation by direct interaction with L-Ficolin
Molecular Immunology, Volume 60, No. 1, Year 2014
Notification
URL copied to clipboard!
Description
Trypanosoma cruzi, the agent of Chagas' disease, the sixth neglected tropical disease worldwide, infects 10-12 million people in Latin America. Differently from T. cruzi epimastigotes, trypomastigotes are complement-resistant and infective. CRPs, T-DAF, sialic acid and lipases explain at least part of this resistance. In vitro, T. cruzi calreticulin (TcCRT), a chaperone molecule that translocates from the ER to the parasite surface: (a) Inhibits the human classical complement activation, by interacting with C1, (b) As a consequence, an increase in infectivity is evident and, (c) It inhibits angiogenesis and tumor growth. We report here that TcCRT also binds to the L-Ficolin collagenous portion, thus inhibiting approximately between 35 and 64% of the human complement lectin pathway activation, initiated by L-Ficolin, a property not shared by H-Ficolin. While L-Ficolin binds to 60% of trypomastigotes and to 24% of epimastigotes, 50% of the former and 4% of the latter display TcCRT on their surfaces. Altogether, these data indicate that TcCRT is a parasite inhibitory receptor for Ficolins. The resulting evasive activities, together with the TcCRT capacity to inhibit C1, with a concomitant increase in infectivity, may represent T. cruzi strategies to inhibit important arms of the innate immune response. © 2014 Elsevier Ltd.
Authors & Co-Authors
Sosoniuk, Eduardo
Chile, Santiago
Facultad de Medicina de la Universidad de Chile
Vallejos, Gerardo
Chile, Santiago
Facultad de Medicina de la Universidad de Chile
Kenawy, Hany Ibrahim
United Kingdom, Leicester
University of Leicester
Egypt, Mansoura
Mansoura University
Gaboriaud, Christine
France, Grenoble
Institut de Biologie Structurale
France, Saint Martin D'heres
Université Grenoble Alpes
Thielens, Nicole M.
France, Grenoble
Institut de Biologie Structurale
France, Saint Martin D'heres
Université Grenoble Alpes
Fujita, Teizo
Japan, Fukushima
Fukushima Medical University
Schwaeble, Wilhelm J.
United Kingdom, Leicester
University of Leicester
Ferreira, Arturo
Chile, Santiago
Facultad de Medicina de la Universidad de Chile
Valck, Carolina E.
Chile, Santiago
Facultad de Medicina de la Universidad de Chile
Statistics
Citations: 48
Authors: 9
Affiliations: 6
Identifiers
Doi:
10.1016/j.molimm.2014.03.014
e-ISSN:
18729142
Research Areas
Cancer